Trial
NCT05668936
A Thorough QTC Study to Assess the Effect of Cotadutide on Cardiac Repolarization in Healthy Participants
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
AstraZeneca
Collaborators
—
Condition
Non-alcoholic Steatohepatitis
Intervention
Cotadutide
Why stopped
Discontinuing the development of cotadutide, a daily injectable GLP-1/glucagon co-agonist, is based on strategic pipeline considerations. The premature closure is not due to any newly observed safety signals or a change in the risk/benefit profile.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-04-05